Menopausal hormone therapy increases risk of breast cancer

Abstract

said the authors. Menopausal hormone therapy Comment increases risk of breast cancer Clinicians must heed the message of this study but Use of menopausal hormonal therapy (MHT) appears also take a rational and comprehensive approach to the to increase risk of breast cancer, according to findings of management of menopausal symptoms, with careful a meta-analysis published in The Lancet.1 consideration of the risks and benefits of initiating MHT The Collaborative Group on Hormonal Factors in for each woman . . . For likely candidates, MHT Breast Cancer searched for published and unpublished (preferably oestrogen alone) should be initiated around prospective epidemiological studies conducted between the time of natural menopause and ideally limited to January 1992 and January 2018 with data on the type 5 years of use, said Joanne Kotsoploulos from the and timing of MHT in postmenopausal women; University of Toronto, Ontario, Canada, in an 58 studies met the selection criteria for the metaaccompanying comment published in The Lancet.3 analysis. Logistic regression was used to evaluate the * oestrogen-receptor positive risk of breast cancer in MHT users compared with those